The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12778904 B1

Date of Patent:

Nov. 03, 2026

Filed:

Dec. 08, 2023

Host directed drug combinations for treatment of viral infections

Applicant:

Systamedic Inc., Clinton, CT (US);

Inventor:

Anton Franz Joseph Fliri, Mystic, CT (US);

Assignee:

SystaMedic Inc., Clinton, CT (US);

Attorney:

Ziegler IP Law Group, LLC.

Primary Examiner:

Brenda L Coleman

Int. Cl.

CPC ...

A61K 31/122 (2006.01); A61K 31/12 (2006.01); A61K 31/167 (2006.01); A61K 31/4745 (2006.01); A61K 31/609 (2006.01); A61P 29/00 (2006.01); A61P 31/12 (2006.01);

U.S. Cl.

CPC ...

A61K 31/122 (2013.01); A61K 31/167 (2013.01); A61K 31/4745 (2013.01); A61P 31/12 (2018.01);

Abstract

Drug combinations, compositions including pharmaceutical compositions as well as methods of using and treating a viral infection, including one of the following: (1) atovaquone with a second group of substances consisting of ademetionine, albendazole, celastrol, cepharantine, chloroquine, cycloheximide, diethylstilbestrol, gemcitabine, homoharringtonine, hydroxy progesterone, imatinib, imipramine, indomethacin, ivermectin, niclosamide, raloxifene, sorafenib, and tipifarnib; or (2) cepharantine with a second group of substances consisting of ademetionine, albendazole, atovaquone, celastrol, chloroquine, cycloheximide, diethylstilbestrol, gemcitabine, homoharringtonine, hydroxy progesterone, imatinib, imipramine, indomethacin, ivermectin, raloxifene, sorafenib, and tipifarnib; or (3) one substance selected from a first group of substances consisting of ademetionine, albendazole, atovaquone, celastrol, cepharantine, chloroquine, cycloheximide, diethylstilbestrol, gemcitabine, homoharringtonine, hydroxy progesterone, imatinib, imipramine, indomethacin, ivermectin, raloxifene, sorafenib, tipifarnib in combination with a second group of substances selected from the group consisting of ademetionine, albendazole, celastrol, cepharantine, chloroquine, cycloheximide, diethylstilbestrol, gemcitabine, homoharringtonine, hydroxy progesterone, imatinib, imipramine, indomethacin, ivermectin, raloxifene, sorafenib, and tipifarnib.

Find Patent Forward Citations

Quick Actions:

Fliri, Anton Franz Joseph. (2026). Host directed drug combinations for treatment of viral infections (U.S. Patent No. 12778904). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12778904

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile